PDX Model DetailsTM00702

Request information on the availability of this model.

PDX Model Summary

Model Details
Model ID (Previous ID)
TM00702 (SK1260F)
Initial Diagnosis
Melanoma
Final Diagnosis
Melanoma
Stage/Grade
AJCC IV /
Primary Site
Skin
Sample Site
Bone
Tumor Type
Metastatic

Publications citing this model

 Ishak Gabra MB; et al. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat Commun. 2020 Jul 3;11(1):3326. doi: 10.1038/s41467-020-17181-w
Malcolm, J; et al. Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX). PeerJ. 2019 Mar 28;7:e6586.  10.7717/peerj.6586

Patient
Sex
Female
Age (at time of tissue collection)
59
Race/Ethnicity
White / Not Reported
Treatment Naïve?
Yes
Current Smoker/Former Smoker
Unknown / Unknown

Engraftment
Host Strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(aka NSG or NOD Scid gamma)
Sample Type
Surgical resection (fragment)
Engraftment Site
no data

Molecular Data (Engrafted Tumor)

Variants

Gene Expression

Platforms: hu133, stRNA_Seq

Hatched bars indicate genes with expression levels determined to be mildly affected by alignment calculations. Details.

Gene CNV

CNV Plots

Tumor Mutation Burden

 no data

Microsatellite Instability

 no data

Gene Fusion

 no data

Model Characterization

Histology

 Summary:
P2 pathology consistent with melanoma.
Pathologist:
Dr. Regina Gandour-Edwards, University of California, Davis

P0 tumor F017 B1260 for PDX model TM00702 stained with H&E.
P2 tumor F017 ID011for PDX model TM00702 stained with H&E.

P2 tumor F017 ID011for PDX model TM00702 stained for KI67.

Dosing Studies

Circos Plots

 no data